Camphor toxicity: Difference between revisions
(ref) |
(clinical feature) |
||
| Line 2: | Line 2: | ||
*Common topical agent for pain relief, wart removal, osteoarthritis, cold sores | *Common topical agent for pain relief, wart removal, osteoarthritis, cold sores | ||
*FDA limits over the counter preparations to 11%<ref>United States Food and Drug Administration. Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Fed Reg 1983</ref> | *FDA limits over the counter preparations to 11%<ref>United States Food and Drug Administration. Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Fed Reg 1983</ref> | ||
*Highly lipophilic, widely and rapidly distributed | *Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes | ||
==Clinical Features== | |||
*Nausea, vomiting, abdominal pain | |||
*Oral burning, headache | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Tox]] | |||
Revision as of 01:43, 22 January 2016
Background
- Common topical agent for pain relief, wart removal, osteoarthritis, cold sores
- FDA limits over the counter preparations to 11%[1]
- Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes
Clinical Features
- Nausea, vomiting, abdominal pain
- Oral burning, headache
References
- ↑ United States Food and Drug Administration. Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Fed Reg 1983